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Background: Group A streptococcus (GAS) is an etiological agent for the immune mediated sequela post
streptococcal glomerulonephritis (PSGN). In some populations PSGN is recognized as a risk factor for chronic kidney
disease (CKD) and end-stage renal disease (ESRD). It was found that a significantly greater proportion of subjects
with past history of PSGN than without the history exhibited seroreactions to streptococcal antigens called
streptococcal inhibitor of complement (SIC) and to distantly related SIC (DRS). These antigens are expressed by
major PSGN-associated GAS types. We therefore predicted that in populations such as India, which is endemic for
streptococcal diseases and which has high prevalence of CKD and ESRD, greater proportions of CKD and ESRD
patients exhibit seroreaction to SIC and DRS than healthy controls.
Methods: To test this we conducted a SIC and DRS seroprevalence study in subjects from Mumbai area. We
recruited 100 CKD, 70 ESRD and 70 healthy individuals.
Results: Nineteen and 35.7% of CKD and ESRD subjects respectively were SIC antibody-positive, whereas only 7%
of healthy cohort was seropositive to SIC. Furthermore, significantly greater proportion of the ESRD patients than
the CKD patients is seropositive to SIC (p=0.02; odds ratio 2.37). No association was found between the renal
diseases and DRS-antibody-positivity.
Conclusions: Past infection with SIC-positive GAS is a risk factor for CKD and ESRD in Mumbai population.
Furthermore, SIC seropositivity is predictive of poor prognosis of CKD patients.
Keywords: Post streptococcal glomerulonephritis, Chronic kidney disease, End-stage renal disease, Protein
creatinine ratio, Streptococcus pyogenes, Streptococcal inhibitor of complementBackground
It is estimated that post streptococcal glomerulonephritis
(PSGN), an immune mediated sequela of Streptococcus
pyogenes (group A streptococcus; GAS) infection, afflicts
about 472,000 people worldwide contributing to approxi-
mately 5000 deaths annually [1]. Because prognosis of
PSGN is generally considered excellent, the disease hasn’t
received much attention among investigators. However, in* Correspondence: sris@qimr.edu.au
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reproduction in any medium, provided the orthe recent decades the knowledge that PSGN is a strong
risk factor for chronic kidney disease (CKD) and end stage
renal disease (ESRD) in some populations has gained cre-
dence [2-5]. A recent prospective study [3] in an Indigen-
ous Australian community found that subjects with history
of PSGN were significantly more likely to present with
overt albuminurea than the corresponding control subjects
(no history of PSGN). Goodfellow et al. [6] found that
mean age of onset of proteinuria is significantly lower in
patients who are seropositive to streptococcal antigens
than in patients who are seronegative, suggesting a role for
streptococcal infection in CKD. With alarmingly highral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7-9], a better understanding of the relationship between
these serious diseases and past S. pyogenes infection may
help to improve management of CKD.
Early epidemiological studies suggested that some GAS
M serotypes, notably M1, M12, M49, M55 and M57, are
associated with PSGN [10]. Of these, M1 and M57 secrete
a protein called streptococcal inhibitor of complement
(SIC) [11,12], and M12 and M55 secrete a protein distantly
related to SIC (DRS) [13]. In an Australian indigenous
population we found significantly greater proportion of
subjects with recorded history of PSGN exhibited DRS
seropositivity than those without the history [14]. Also,
anti-SIC IgM was found to be positively associated with
PSGN in Swedish children [15]. Thus, there may be a pos-
sible role for SIC, DRS or both in the pathogenesis
of PSGN.
As SIC and DRS are highly immunogenic in humans
[14,16] and their immune responses are likely to be per-
sistent, serology to these antigens may offer a convenient
method to test the hypothesis that seropositivity to SIC
or DRS is more prevalent in CKD and ESRD patients
than in control subjects. A small comparative study
between haemodialysis patients and control subjects
from Northern Queensland [17] offers credence to this
hypothesis. Furthermore, India with its large population-
base, high streptococcal disease burden and high inci-
dence and prevalence of CKD and ESRD [18], provides a
unique opportunity to conduct this study. Our results
show positive association between SIC seropositivity and
chronic renal disease. Furthermore we conclude poor
prognosis of SIC-seropositive CKD patients compared to
seronegative CKD patients.
Methods
GAS strains, study subjects and sera
GAS isolates were recovered from school children to de-
termine circulating types in the community during the
study period. GAS strains were typed using the emm typ-
ing scheme [19,20]. Approval for swabbing of individuals
in the study was granted (EC/Gov/-4/2006) by the Seth G. S.
Medical College and KEM Hospital Ethics Committee,
India. Written informed consent for swabbing was obtained
from the guardians of all children included in the study.
Patients were assessed for renal impairment by a)
persistent abnormal serum creatinine levels, b) persistent
uremic symptoms (presence of RBCs, pus cells and
epithelial cells, proteinurea, increased urine protein:cre-
atinine ratio (PCR)), and c) estimated glomerular filtra-
tion rates below 60 ml/min/1.73m2 [21] for more than or
equal to three months. These clinical parameters were
used for diagnosis of CKD and ESRD patients as per
KDOQI Guidelines (http://www.kidney.org/professionals/
kdoqi/guidelines_commentaries.cfm).Sera samples from patients and healthy individuals were
collected at the KEM hospital and stored at −80°C until
used. The study was conducted under ethics approval
from Seth G.S. Medical College & KEM Hospital (refer-
ence number, EC/GOVT-4/2010). Informed consent was
obtained from healthy, CKD and ESRD cohorts.
Urinary protein creatinine ratio (PCR)
Protein and creatinine in urine samples were measured
according to Pesce et al. [22] and Husdan and Rapoport
[23] respectively. The PCR for healthy individuals is de-
fined as <0.2mg protein/1mg creatinine.
Measurement of anti-SIC & anti-DRS levels in human sera
samples
Serum antibody titers for SIC and DRS was measured as
described by Sriprakash et al. [14]. Briefly, high binding flat
bottomed immune plates (Himedia) were coated by adding
100 μl of recombinant SIC or DRS [24,25] (100 μg/ml; in
carbonate buffer, pH 9.6) per well and incubating overnight
at 4°C. After blocking with denatured casein hydrolysate
(5% in PBS) for 2 hours, the bound protein was allowed to
react with a 1 in 300 dilution of human serum for 1 hour
in the same buffer containing 0.05% Tween-20 at room
temperature. After washing 5 times with 0.05% Tween-20
in PBS, secondary anti-human IgG antibody conjugated
with peroxidase (Sigma-Aldrich) was added and the reac-
tions were detected with 3,3',5,5'-tetramethylbenzidine
(Sigma-Aldrich). The reaction was terminated with stop-
ping solution after 30min incubation and optical density
(OD) was measured at 450 nm.
Statistical analysis
Seropositivity based on OD values relies on the use of a
cutoff. Due to potential cutoff inflation by the presence of
seropositive healthy people, a conservative approach was
chosen. This was determined by taking two standard devi-
ations above the mean OD among healthy patients for
both SIC and DRS separately then applying those cutoffs
to OD values for the CKD and ESRD groups. Differences
in characteristics between groups were assessed via tests
appropriate to the data. A chi-square test was used for
proportions (sex, diabetes) and the Mann–Whitney test
was used for skewed variables (age, disease duration). The
association between SIC or DRS and each category of
renal disease was assessed by calculating odds ratios (OR)
for each of the four combinations, and the significance of
each association was assessed by Pearson’s chi-square test.
Although for some comparisons the expected cell counts
in the two by two tables were less than five, p-values from
Fisher’s exact test gave similar results to those from
Pearson’s chi-square test. We also examined these associa-
tions after adjusting for the effects of age and sex through
logistic regression. Since none of the controls had diabetes







Age, median (IQR) 31 (26–40) 45 (38–55) 45 (36–52)
Sex ratio, M:F 2.2 1.7 1.8
SIC positivity, n (%) 5 (7.1) 19 (19.0) 25 (35.7)
DRS positivity, n (%) 3 (4.3) 7 (7.0) 5 (7.1)
Diabetes history, n (%) 0 (0) 29 (29.0) 13 (18.6)
Disease duration,
median yrs (IQR)
N/A 3 (1–4) 3 (2–5)
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we assessed the effect of diabetes on seropositivity to SIC
or DRS among CKD or ESRD patients with logistic regres-
sion. Initially univariate models were used to look at the
separate (unadjusted) effects of diabetes on SIC or DRS re-
activity for each disease group. We then looked at the














In all we recruited 100 CKD and 70 ESRD patients at-
tending the clinics at the KEM hospital and 70 healthy
subjects. CKD and ESRD status was assessed by percep-
tible (>1+) precipitation reaction for protein in urine,
PCR of >0.2 mg/mg creatinine, positivity for epithelial
cells, red blood cells or pus in urine and estimated
glomerular filtration rate. The median disease duration
as per medical records for CKD and ESRD was 3 years for
both with inter-quartile range of 1–4 and 2–5 respectively
(p=0.25 by Mann–Whitney test; Table 1). All ESRD pa-
tients were undertaking dialysis. Twenty nine percent of
CKD and 18.6% of ESRD patients were diagnosed as dia-
betics while none of the controls had a history of diabetes
(Table 1). The diabetes prevalence was marginally higher
in CKD than the ESRD patients (chi-square test p=0.12).Table 2 emm type distribution in two cross-sectional
surveys
emm types Number of
isolates
Current survey (2010–2012) N=27
63.3; 82.1; st9505; 42.3; 22; 49.4; 12 3 isolates each
15; 106; 53.9; 73; 86.2; 119.2; st11014; st854; 109.1; 53 2 isolates each
15.1; 60.3; 66; 73.1; 9; st1731.3; stKNB6.0; 1; 3; 118.5 1 isolate each
Previous survey (2006–2008; [26]) N=15
87; 81.2 4 isolates each
25.1 2 isolates each
St9505; 2904; 60.3; 4.4; st211.1; 69; 49; 9; 109.1; 42; 4.5; 44 1 isolate each
SIC and DRS-positive types (emm1 and emm12) are in bold and underlined.The median age of both CKD and ESRD patients was 45
years and this was significantly higher than healthy con-
trols (Mann–Whitney test p<0.001 for both). The male:fe-
male ratios were 1.7 and 1.6 for CKD and ESRD patients
respectively and these did not significantly differ from
healthy controls (chi-square test p>0.3 for both).
All the 70 control subjects (median age 31 and male:fe-
male ratio 2.2) showed no more than traces of proteinurea
and PCR less than 0.2mg/mg creatinine). As all the three
groups (control, CKD and ESRD) are from Mumbai and
surrounding areas, it is assumed that they would have
been exposed to a similar range of prevalent GAS types
over the years. Of particular interest is to determine
whether this population is likely to be exposed to the types
capable of producing SIC (emm1 and emm57) or DRS
(emm12 and emm55).
Prevalence of SIC or DRS producing GAS types in Mumbai
During the current study period we recovered from
Mumbai schoolchildren 51 GAS isolates belonging to 27
emm types (Table 2). In our previous study [26] 15 emm
types were recovered from the same population, and only
3 types are common between these two cross sectional sur-
veys. Taken together, we conclude that GAS isolates in this
region are highly divergent as in the rest of the country
[27]. However, in these recent two Mumbai-based cross-
sectional surveys only a minority of the isolates recovered
had the genetic capability to produce SIC or DRS (one iso-
late of emm1 and 3 isolates of emm12; Table 2). Similar
studies conducted on isolates from different parts of India
















Figure 1 Proportion of SIC and DRS sero-positive in Healthy,
CKD and ESRD cohorts: The cutoff values for SIC and DRS
seropositivity are based on the respective titers in the healthy
cohort, and were determined as described in the methods
section. P values are only given for the groups (bars) showing
significant differences.
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a DRS-positive type, was recovered [28-33].
SIC and DRS seroprevalence among the healthy subjects
from Mumbai area
Using the cutoff described in the methods section we found
that 7.1% and 4.3% of our healthy cohort (n=70) were posi-
tive to SIC and DRS antibodies (Figure 1). Despite low
isolation rates of SIC- and DRS- strains, high rates of sero-
conversion to these antigens is not surprising given that
they elicit strong and persistent antibody responses. As
orthologues of SIC and DRS genes haven’t been found in
other organisms thus far, these results suggest that our
study population would have been exposed to SIC or DRS
producing GAS serotypes sometime in the past.
SIC and DRS seroprevalence among the CKD and ESRD
patients
We further analysed SIC and DRS seroprevalence among
CKD and ESRD cohorts. The results revealed that sera
from 19% of CKD patients (n=100) and 35.7% of ESRD pa-
tients (n=70) reacted with SIC antigen. Thus, relative to
the healthy controls significantly high proportion of CKD
and ESRD patients are SIC antibody-positive (chi-square
p=0.03 and <0.001 respectively) (Figure 1). Antibody posi-
tivity to SIC seems to predict increased predisposition for
both CKD and ESRD, the OR being 3.05 (95% CI 1.08,
8.61; p=0.04) and 7.22 (95% CI 2.57, 20.28; p<0.001) re-
spectively relative to the healthy group. After adjustment
for age and sex the ORs showed a similar although some-
what reduced effect: 2.33 (95% CI 0.75, 7.22; p=0.14) and
3.95 (95% CI 2.16, 21.24; p<0.001) respectively. By con-
trast, seropositivity to DRS in CKD or ESRD was not sig-
nificantly different to that in the healthy group whether
adjusted for age and sex or not (p>0.3 in all cases).
There was no evidence in this study that SIC seroposi-
tivity differed by diabetes status between CKD or ESRD
patients in either the unadjusted or adjusted logistic re-
gression models. This suggests that the prevalence of SIC
seropositivity is independent of age, sex and diabetes sta-
tus in the study sample of people with renal disease.
Since stage V CKD patients on dialysis are considered as
ESRD patients, we anticipated that the proportion of SIC-
positive individuals within each of these cohorts to be
similar. However contrary to our expectation, we found
that the proportion of SIC-positive ESRD patients is sig-
nificantly greater than the proportion of SIC-positive CKD
patients (p=0.02; odds ratio 2.37 (95% CI 1.18, 4.77)).
These results suggest that SIC seropositive CKD patients
may progress to ESRD more readily than the SIC sero-
negative CKD patients.
Lack of correlation between CKD and DRS seropositiv-
ity is surprising as the latter is shown to be associated with
past history of PSGN in the Australian Indigenouspopulation [14]. It is possible that in Mumbai area DRS-
positive S. pyogenes (emm12 and emm55) may not be
major types responsible for PSGN. In fact, S. dysgalactiae
subspecies equisimilis (SDSE) is 8 fold more often recov-
ered from the throats of schoolchildren than GAS [26].
SDSE is also known to be an aetiological agent for PSGN
[34]. Whereas none of SDSE strains has genetic endow-
ment for SIC expression [35], some strains may possess
genes for a DRS-like proteins [36]. However the DRS-like
protein from SDSE is immunologically distinct and the
antibodies do not cross-react with GAS DRS (our unpub-
lished data). Given these findings, seroprevalence studies
against SDSE DRS-like protein is worthwhile, and is the
subject of our future study.
Conclusions
In conclusion we show that past streptococcal infection is
an independent risk factor for CKD and ESRD in Mumbai
area. Furthermore, our results suggest that SIC serology
may have a predictive value for poor prognosis of CKD pa-
tients. Early diagnosis of CKD followed by serology to SIC
for the Indian population may help a better management
of the patients to prevent possible progression to ESRD. A
similar study in other endemic regions for these diseases is
warranted before this recommendation is adopted into
general clinical practice.Competing interests
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